YouTube video by LUCIODALLAVEVO

NEXERA-303 is evaluating INCA33890 plus FOLFOX and bevacizumab vs chemotherapy and bevacizumab alone in previously untreated MSS mCRC.

'Cancer in a time of conflict: from political economy to systems engineering'

Gastrointestinal oncologists weigh HER2 testing practices, the order of HER2-directed therapies, and emerging agents for metastatic colorectal cancer.

'Cancer in a time of conflict: from political economy to systems engineering'

Explore PhD opportunities at the CRUK Manchester Centre, meet current researchers and students, and take the next step towards your future i

Researchers at Hokkaido University, in collaboration with an international team of scientists led by the University of South Florida Health and Tampa General Hospital, have uncovered an important mechanism behind immune evasion in metastatic colorectal cancer (mCRC). Their findings challenge a 30-year-old theory in cancer. Thirty years ago, the "rheostat" model proposed that elevated sphingosine-1-phosphate (S1P) promotes tumor cell growth, whereas higher ceramide levels trigger cell death. Under this traditional model, scientists thought that cancer cells used this internal mechanism to control their own fate, turning up S1P to grow uncontrollably or turning down ceramide to avoid dying, just like a physical rheostat, or dimmer switch, controls electrical current by increasing or decreasing resistance. The new, multi-institute study showed that the rheostat does not primarily function within the cancer cells themselves. Instead, the imbalance of increasing S1P and decreasing long-chain ceramide occurs within the tumor microenvironment, where S1P creates a localized biochemical barrier that prevents the immune system from attacking the tumor. By examining 574 human colon cancer tissue samples with advanced mapping technology, the team found that as colorectal cancer spreads, levels of pro-cancer growth lipids increased, whereas levels of the cancer cell-killing lipid dropped significantly. The old theory...

The Honourable Paul Lane, Speaker of the House of Assembly, advises that the 2026 Members’ Compensation Review Committee (MCRC) has delivered its final report, which is available on the House of…

Conditional approvals in Armenia cover botensilimab plus balstilimab indicated for patients with MSS mCRC without active liver metastases.

In the initial report, 148 patients were treated, and 101 patients were response evaluable with at least 6 months of follow-up and had received a median of 3

YouTube video by Manchester Cancer Research Centre

Researchers at Hokkaido University, in collaboration with an international team of scientists led by the University of South Florida Health and Tampa General Hospital, have uncovered an important mechanism behind immune evasion in metastatic colorectal cancer (mCRC). Their findings challenge a 30-year-old theory about cancer.

Researchers at Hokkaido University, in collaboration with an international team of scientists led by the University of South Florida Health and Tampa General Hospital, have uncovered an important mechanism behind immune evasion in metastatic colorectal cancer (mCRC).

Background: Older patients with metastatic colorectal #Cancer (mCRC) are a heterogeneous population with wide variability in functional status, frailty, cognition, nutritional reserve, and comorbidity burden. Treatment decisions are often guided primarily by chronological age and performance status, which may not adequately capture vulnerability or patient-centered outcomes in this population. Objective: The primary aim of this #Study is to prospectively evaluate the association of baseline geriatric assessment (GA)–derived frailty with overall survival in older patients with mCRC receiving first-line systemic therapy in routine clinical practice; secondary aims are to evaluate the associations of frailty with initial treatment intensity and early changes in quality of life (QOL). Methods: Baseline GA includes activities of daily living, instrumental activities of daily living, the Clinical Frailty Scale, the Mini-Cog, nutritional assessment, the Charlson Comorbidity Index (excluding #Cancer-related items), and the Eastern Cooperative Oncology Group (ECOG) performance status. Blood-based prognostic biomarkers, including the prognostic nutritional index and neutrophil-to-lymphocyte ratio, are also collected. Initial treatment intensity is defined according to the first-line systemic regimen selected at baseline, whereas subsequent local therapies are recorded separately. QOL is assessed using the European Organisation for #Research and Treatment of #Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) at baseline and 8 to 12 weeks after treatment initiation. Results: This #Study was registered in the UMIN Clinical Trials Registry (UMIN000060489) on April 1, 2026. This #Study received no external funding. Participant recruitment began on April 1, 2026 (the first participant enrolled in June 2026) and is planned to continue for approximately 2.5 years (projected completion: October 2028), with an anticipated sample size of approximately 100 participants; an early QOL follow-up is scheduled for 8 to 12 weeks after treatment initiation for each participant. As of the submission of this revised manuscript (August 2026), 4 participants had been enrolled, baseline QOL assessments had been completed for all 4 participants, and the 8- to 12-week follow-up QOL assessments had been completed for 3 participants; no outcome data were available. Analysis of the primary outcome will be conducted after final survival follow-up, with the main results anticipated for publication in 2030. Conclusions: This #Protocol describes a pragmatic GA-based observational framework to examine associations between pretreatment vulnerability, initial treatment intensity, survival outcomes, and patient-reported QOL in older patients with mCRC. Given the exploratory, hypothesis-generating design, the #Study is expected to generate clinically relevant hypotheses for individualized, patient-centered treatment strategies and future geriatric oncology #Research. Trial Registration: UMIN Clinical Trials Registry UMIN000060489; https://tinyurl.com/3mn563er

The c-Met–directed ADC-based combination was designated for mCRC previously treated with fluoropyrimidine, irinotecan, oxaliplatin, and anti-VEGF therapy.

Moh’d Khushman, MD, discusses the rationale for investigating INCA33890 plus FOLFOX/bevacizumab in the phase 3 setting in patients with MSS/pMMR mCRC.